To study the potential mechanism of action of the m6A-associated genes in PAAD, the genetic mutation analysis shown in Figures 6(a) and 6(b) reveals that the mutation percentages of HNRNPC, IGF2BP2, IGF2BP3, KIAA1429, METTL3, METTL16, PCIF1, and YTHDF1 were 1.8%, 2.4%, 1.2%, 5%, 1.2%, 0, 0.6%, and 1.8%, respectively. This evidence concerns the gene METTL16 and pancreatic adenocarcinoma.